Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Antibiotic Treatment of Recurrent Episodes of Asthma in Children (AB-studie)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Professor Hans Bisgaard, Copenhagen Studies on Asthma in Childhood Identifier:
First received: November 2, 2010
Last updated: July 27, 2015
Last verified: July 2015
Copsac has discovered that asthmatic exacerbations are as closely linked to bacterial as to viral infection. The current study will examine whether treatment of asthmatic exacerbations with macrolide antibiotics - in the abscence of clear clinical bacterial infection which would in any case precipitate antibiotic treatment - has an effect on either the particular episode, or subsequently. Macrolide antibiotics are chosen for ease of administration ensuring high compliance, antibiotic appropriacy, and anti-inflammatory properties.

Condition Intervention Phase
Childhood Asthma With Acute Exacerbation
Drug: Azithromycin
Other: Placebo mixture
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Antibiotic Treatment of Recurrent Episode of Asthma in Children - a Randomised, Case-controlled Study Within the COPSAC2010 Cohort (Asthma Begins in Childhood)

Resource links provided by NLM:

Further study details as provided by Copenhagen Studies on Asthma in Childhood:

Primary Outcome Measures:
  • Symptom scoring [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • Duration in days of each asthmatic episode from randomisation start [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • need for PO steroids during the episode [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • beta-agonist use during the asthmatic episode [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • time lapse until the next asthmatic episode [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • MD assessment of the episode [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • Family's assessment of the episode [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • Asthma related health and economic assessment [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • percentage of time away from kindergarten or, for the parents, away from work [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]
  • stratification of the above parameters according to bacterial colonisation of the airways [ Time Frame: 1 to 3 years of age ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: November 2010
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Antibiotics
Azithromycin (10 mg/kg once a day for 3 days)
Drug: Azithromycin
10 mg/kg peroral for 3 consecutive days
Placebo Comparator: Placebo
Placebo mixture (once a day for 3 days)
Other: Placebo mixture
Placebo mixture containing no active substance.


Ages Eligible for Study:   1 Year to 3 Years   (Child)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participation in the COPSAC2010 cohort
  • recurrent wheeze
  • and others

Exclusion Criteria:

  • Macrolide allergy
  • Heart, liver or kidney disease.
  • and others
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01233297

Copsac, DBAC
Gentofte, Copenhagen, Denmark, 2820
Copsac, Næstved Hospital, Pediatric Department
Naestved, Denmark, 4700
Sponsors and Collaborators
Copenhagen Studies on Asthma in Childhood
Principal Investigator: Hans Bisgaard, MD, DMSc Copenhagen Studies on Asthma in Childhood
  More Information

Responsible Party: Professor Hans Bisgaard, MD, DMSc, Copenhagen Studies on Asthma in Childhood Identifier: NCT01233297     History of Changes
Other Study ID Numbers: 2010-018592-16 
Study First Received: November 2, 2010
Last Updated: July 27, 2015
Health Authority: Denmark: Danish Medicines Agency
Denmark: Danish Dataprotection Agency
Denmark: Ethics Committee

Keywords provided by Copenhagen Studies on Asthma in Childhood:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents processed this record on January 14, 2017